Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
113.95 EUR | +2.38% |
|
+2.62% | -18.76% |
09/07 | Merck KGAA and preparations for the post-Keytruda era | ![]() |
07/07 | European share rise on tech, banks boost with focus on US trade negotiations | RE |
Capitalization | 4.84TCr 5.67TCr 4.51TCr 4.17TCr 7.76TCr 4,85600Cr 8.68TCr 54TCr 21TCr 2,26900Cr 21TCr 21TCr 8,30100Cr | P/E ratio 2025 * |
15.6x | P/E ratio 2026 * | 14.1x |
---|---|---|---|---|---|
Enterprise value | 5.45TCr 6.38TCr 5.08TCr 4.7TCr 8.74TCr 5,46800Cr 9.77TCr 61TCr 23TCr 2,55500Cr 24TCr 23TCr 9,34700Cr | EV / Sales 2025 * |
2.52x | EV / Sales 2026 * | 2.33x |
Free-Float |
29.72% | Yield 2025 * |
2.1% | Yield 2026 * | 2.18% |
More valuation ratios
* Estimated data
More news
Last Transcript: Merck KGaA
More recommendations
More press releases
1 day | +1.44% | ||
1 week | +1.81% | ||
Current month | +2.50% | ||
1 month | -3.09% | ||
3 months | +0.27% | ||
6 months | -20.90% | ||
Current year | -19.41% |
1 week | 108.5 | ![]() | 114.2 |
1 month | 108.1 | ![]() | 116.85 |
Current year | 108.1 | ![]() | 154.65 |
1 year | 108.1 | ![]() | 177 |
3 years | 108.1 | ![]() | 202.8 |
5 years | 107.5 | ![]() | 231.5 |
10 years | 70.68 | ![]() | 231.5 |
Manager | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 01/05/2021 | |
Director of Finance/CFO | 55 | 01/07/2023 | |
Laura Matz
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2021 |
Director | Title | Age | Since |
---|---|---|---|
Christian Raabe
BRD | Director/Board Member | - | 26/04/2019 |
Jürgen Glaser
BRD | Director/Board Member | 62 | 01/05/2012 |
Director/Board Member | 76 | 09/05/2014 |
Name | Weight | AuM | 1st Jan change | |
---|---|---|---|---|
2.01% | 0 M€ | +76.35% | - | |
2.01% | 1 M€ | 0.00% | - | |
1.8% | 962 M€ | -.--% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+1.44% | +1.81% | -24.40% | -36.17% | 5.67TCr | ||
-0.86% | -0.30% | -19.87% | -21.47% | 895.39Cr | ||
+1.40% | +5.09% | +7.00% | +9.27% | 697.18Cr | ||
+2.63% | +2.44% | +23.39% | +110.11% | 594.22Cr | ||
+1.19% | +1.96% | +16.23% | +19.04% | 534.36Cr | ||
+3.13% | +2.13% | +85.70% | -0.63% | 340.05Cr | ||
+1.81% | +1.87% | +22.41% | +8.36% | 204.58Cr | ||
-0.18% | +1.02% | -7.18% | +13.24% | 202.86Cr | ||
+0.50% | -1.50% | +42.69% | -28.15% | 187.44Cr | ||
+4.88% | +27.17% | +188.83% | -24.21% | 181.5Cr | ||
Average | +1.59% | +1.86% | +33.48% | +4.94% | 950.26Cr | |
Weighted average by Cap. | +1.36% | -0.06% | -5.69% | -15.53% |
2025 * | 2026 * | |
---|---|---|
Net sales | 2.16TCr 2.53TCr 2.01TCr 1.86TCr 3.46TCr 2,16600Cr 3.87TCr 24TCr 9.16TCr 1,01200Cr 9.48TCr 9.28TCr 3,70300Cr | 2.24TCr 2.62TCr 2.09TCr 1.93TCr 3.59TCr 2,24600Cr 4.01TCr 25TCr 9.5TCr 1,04900Cr 9.83TCr 9.62TCr 3,83900Cr |
Net income | 308.12Cr 360.71Cr 287.14Cr 265.57Cr 494.26Cr 31TCr 552.54Cr 3.44TCr 1.31TCr 14TCr 1.35TCr 1.32TCr 53TCr | 340.59Cr 398.73Cr 317.4Cr 293.55Cr 546.35Cr 34TCr 610.77Cr 3.8TCr 1.45TCr 16TCr 1.5TCr 1.46TCr 58TCr |
Net Debt | 609.62Cr 713.67Cr 568.11Cr 525.42Cr 977.9Cr 61TCr 1.09TCr 6.8TCr 2.59TCr 29TCr 2.68TCr 2.62TCr 1,04600Cr | 374.62Cr 438.56Cr 349.11Cr 322.88Cr 600.93Cr 38TCr 671.79Cr 4.18TCr 1.59TCr 18TCr 1.64TCr 1.61TCr 64TCr |
More financial data
* Estimated data
Employees
62,604
Sector
Pharmaceuticals
Calendar
07/08
- Q2 2025 Earnings Call
Date | Price | Change | Volume |
---|---|---|---|
10/25/10 | 113.70 € | +2.16% | 1,38,256 |
09/25/09 | 111.30 € | -0.27% | 3,99,717 |
08/25/08 | 111.60 € | +2.06% | 5,67,324 |
07/25/07 | 109.35 € | -1.71% | 5,67,830 |
04/25/04 | 111.25 € | +0.45% | 2,35,652 |
Delayed Quote Xetra, July 10, 2025 at 06:12 pm IST
More quotesSell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
111.30EUR
Average target price
156.56EUR
Spread / Average Target
+40.67%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition